Global Chronic Obstructive Pulmonary Disease Drugs Market to Grow by $66.54 Billion During 2023-2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027” report has been added to ResearchAndMarkets.com’s offering.

The chronic obstructive pulmonary disease drugs market is forecast to grow by $6654.49 mn during 2022-2027, accelerating at a CAGR of 6.09% during the forecast period. The publisher’s report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of COPD, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.

The publisher’s chronic obstructive pulmonary disease drugs market is segmented as below

By Product

• Combination therapy
• Monotherapy

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and the growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The publisher’s report on the chronic obstructive pulmonary disease drugs market covers the following areas:

• Chronic obstructive pulmonary disease drugs market sizing
• Chronic obstructive pulmonary disease drugs market forecast
• Chronic obstructive pulmonary disease drugs market industry analysis

The publisher’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Ltd., Philip Morris International Inc., Shionogi and Co. Ltd., Sumitomo Pharma Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. The publisher’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Key Topics Covered:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Product

7 Market Segmentation by Distribution Channel

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Vendor Landscape

12 Vendor Analysis

13 Appendix

Companies Mentioned

• AstraZeneca Plc
• Exela Pharma Sciences LLC
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd.
• Innoviva Inc.
• Lupin Ltd.
• Merck and Co. Inc.
• Mundipharma International Ltd.
• Novartis AG
• Theravance Biopharma Inc.
• Vertex Pharmaceuticals Inc.
• Viatris Inc.
• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Ltd.
• CHIESI Farmaceutici SpA
• Cipla Ltd.
• Philip Morris International Inc.
• Shionogi and Co. Ltd.
• Sumitomo Pharma Co. Ltd.
• Teva Pharmaceutical Industries Ltd.

   

For more information about this report visit https://www.researchandmarkets.com/r/i5pxsg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900